Embracing more treatment choices for metastatic, recurrent, or persistent cervical cancer
Mené en Chine sur 445 patientes atteintes d'un cancer du col de l'utérus persistant, récidivant ou métastatique (âge : 18-75 ans), cet essai randomisé de phase III évalue l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité de l'ajout de cadonilimab (un anticorps bispécifique ciblant PD-1 et CTL-4) à une chimiothérapie standard de première ligne avec ou sans bévacizumab
Cervical cancer ranks as the fourth most common cancer among women globally, yet prognosis remains dire for those with recurrent or metastatic disease, evidenced by a mere 19% 5-year survival rate.1 This stark reality underscores the urgent need for novel and enhanced therapeutic options. Since 2014, three landmark phase 3 randomised controlled trials have notably influenced first-line treatment strategies for recurrent or metastatic cervical cancer: GOG-240,2 KEYNOTE-826,3 and BEATcc.4 The GOG-240 trial established the combination of chemotherapy and bevacizumab as the standard first-line intervention for incurable recurrent or metastatic cervical cancer, with a median overall survival of 17 months.2 Subsequently, the KEYNOTE-826 trial showed that adding pembrolizumab to chemotherapy (with or without bevacizumab) markedly improved median overall survival to approximately 26 months.3 Moreover, the BEATcc study evaluated the incorporation of the PD-L1 antibody atezolizumab into first-line chemotherapy combined with bevacizumab, resulting in substantial improvements in overall survival, with a median overall survival of 32·1 months